| INTRODUCTION
People with diabetes are at increased risk of developing disabling and life-threatening health problems, including microvascular and macrovascular complications. 1, 2 Good control of hyperglycaemia and the associated risk factors in type 2 diabetes (T2DM) has been shown to reduce the risk of these complications. 1, 3 Thus anti-hyperglycaemic treatment strategies should ideally also address the management of cardiovascular risk factors, including body weight, blood pressure and lipids. 4 Novel antihyperglycaemic glucagon-like peptide-1 receptor agonist (GLP-1RA) therapies, including exenatide (EXE) and liraglutide (LIRA), have the potential to address these challenges. [5] [6] [7] [8] [9] The combination of GLP-1RA and insulin treatments represents a promising glycaemic management strategy because of the complementary mechanisms of actions of these therapies. 10 Both therapies affect body weight, but in opposite directions; while significant weight reductions have been observed in patients treated with GLP-1RA, insulin is known to significantly increase body weight.
11,12
A meta-analysis of clinical trials conducted by Eng et al. 13 showed that the combination of a GLP-1RA with basal insulin resulted in robust glycaemic control without increased risk of hypoglycaemia or weight gain. The effectiveness of adding GLP-1RA to basal insulin therapy on glucose and weight control in patients with T2DM has also been evaluated in a number of observational and real-world data-based studies. 10, [14] [15] [16] [17] [18] [19] [20] The intensification of insulin therapy by addition of GLP-1RA, rather than adding mealtime insulin, has been shown to be an attractive therapeutic option, 13, 21 and is now recommended in international guidelines: "The available data now suggest that either a GLP-1 receptor agonist or prandial insulin could be used in this setting [in patients not achieving target glycated haemoglobin (HbA1c)], with the former arguably safer, at least for short-term outcomes." 21 A significant number of patients treated with GLP-1RAs also intensify therapy by adding insulin, or switching to insulin therapy, primarily because of sub-optimal glycaemic control; however, to the best of our knowledge, only three observational studies (n = 44 to n = 432) have evaluated the effectiveness of adding insulin to GLP-1RA therapy. 20 Moreover, these studies did not explore the HbA1c 
| MATERIALS AND METHODS

| Data source
The Centricity Electronic Medical Record (CEMR) database was used for this study. The CEMR represents a variety of ambulatory medical practices from 49 US states, including solo practitioners, community clinics, academic medical centres and large integrated delivery networks. The CEMR database consists of >35 000 physicians and other providers, of whom~75% are primary care providers. The database has been extensively used for academic research worldwide. 5, [22] [23] [24] The CEMR database contains detailed prescription information with dates of prescription, including information on medications that were purchased over the counter or prescribed outside of the EMR network. The main medication information data set stores individual records in the form of start/stop dates, along with several specific fields to track treatment adjustments and alterations over time. 
| Statistical methods
While complete data on HbA1c and body weight were available at index date (by design), the proportion of patients with missing longitudinal data on body weight, SBP, LDL cholesterol and HbA1c over 24 months of follow-up ranged from 9% to 19%. The missing longitudinal follow-up data were imputed using the multiple imputation approach, with adjustments for age at index date and use of oral antihyperglycaemic drugs during follow-up. All primary analyses were conducted using the imputed data, with additional analyses conducted for sensitivity assessment based on complete cases. 
| RESULTS
In the cohort of 66 583 patients with minimum 6 months of treatment with GLP-1RA, the mean (standard deviation) age was 56 (11) years, 28 959 (43%) were male, 45 291 (68%) were white, 51 719 (87%) were obese, 3404 (26%)/858 (7%) had micro-/macroalbuminuria, and 17 415 (26%) had a history of hypertension at the time of initiation of GLP-1RA treatment ( Table 1 ). The use of different medications during GLP-1RA therapy, along with their durations of treatment, are shown in Table 1 .
| Glycaemic control
With Figure 1A ).
Those who added insulin within 6 months of GLP-1RA initiation were 18% (odds ratio 1.18; 95% CI 1.09, 1.28; P < 0.001) more likely to achieve HbA1c below 7% at 24 months of follow-up, compared with those who added insulin treatment later.
The 6-monthly trajectories (mean, 95% CI) of HbA1c levels for those who switched to insulin therapy within 24 months (n = 2483; mean time to insulin 14 months; Table 3 ) are shown in Figure 1B . In these patients, the mean HbA1c increased to 9.3% at the time of switching to insulin from a mean HbA1c of 8.5% at GLP1-RA initiation, and 80% of them had HbA1c above 8% at insulin initiation (Table 3) .
Notably, these patients did not achieve better glycaemic control at 24 months compared with their glycaemic status at index date ( Figure 1B ,C). In contrast, patients who added insulin within 24 months of follow-up (n = 36 113; mean time to insulin 3 months; Table 3) experienced a significant HbA1c reduction of 0.55% (95% CI 0.54, 0.57) at 24 months compared with the index date ( Figure 1C ). The adjusted means (95% CI) of change in HbA1c and body weight at 6, 12 and 24 months after GLP-1RA initiation, for those who ceased GLP-1RA after 6 months of initiation and switched to insulin between 6 and 12, 12 and 18, and 18 and 24 months, are shown in Table S1 .
| Weight change
With a baseline body weight of 109 kg ( 
| Associations of glucose and weight loss
Among patients with a minimum of 12 months of GLP-1RA treatment, 78% and 67% had reductions in HbA1c and body weight, respectively, from the index date, while 53% had reductions in both body weight and HbA1c (similar in patients treated with LIRA and EXE; Figure 1D ). At 12 months of follow-up, 8% and 7% of patients did not have reductions in both HbA1c and weight in the EXE and LIRA groups, respectively.
| Cardiovascular risk factors
With a mean 129 mm Hg SBP level at index date, only 24% had SBP ≥140 mm Hg. The adjusted average reduction in SBP was~3 mm Hg consistently over 6, 12 and 24 months of follow-up, and was similar across EXE and LIRA groups (Tables 1 and 4 HbA1c < 7% at 6 months for those whose HbA1c was ≥7.5% at GLP-1RA initiation, n (%)
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4156 (21) 2236 (19) 1920 (24) 3451 (22) 1987 (20) 1464 (25) 2338 (24) 1594 (22) 744 ( (26) 2770 (26) 1059 (27) 1960 (29) 1577 (28) 383 (32) GLP-1RA + INS ---3462 (22) 2083 (21) 1379 (24) 2401 (24) 1679 (23) 722 ( This study showed that addition of insulin and switch to insulin occurred at elevated HbA1c levels of 8.8% and 9.3%, respectively, with a significant proportion of patients having HbA1c above 8%/ 8.5% (71%/58% in the GLP-1RA + INS group and 80%/68% in the GLP-1RA ! INS group). This clearly raises the issue of therapeutic inertia. 25, 26 Given the high glycaemic burden in this population, the time to intensification of therapy requires further evaluation, in conjunction with the factors that might prevent early intensification with insulin therapy, including fear of weight gain and hypoglycaemia.
Notably, the distributions of body weight were similar between those who switched to, or added insulin, and those who remained on GLP-1RA treatment only (Table 1) . Moreover, observed adjusted weight reductions in patients who added insulin were consistently and marginally greater than in those treated with GLP-1RA only during the follow-up period (Table 4) . Our findings in terms of weight loss are consistent with a recent study reporting no weight gain after initiation of insulin in obese patients with T2DM 27 and the systematic review by Balena et al. 20 The limitations of this study include non-availability of complete and reliable data on: (1) Weight loss ≥5% at 6 months, n (%)
GLP-1RA only 5539 (15) 3957 (15) 1582 (15) 3978 (15) 2980 (15) 998 (15) 2050 (16) 1684 (16) 366 (17) GLP-1RA + INS 5241 (18) 3085 (17) 2156 (19) 4413 (18) 2729 (17) 1684 (20) 2985 (19) 2124 (18) 861 ( 4644 (24) 1506 (23) 3204 (25) 2662 (26) 542 (25) GLP-1RA + INS ---6404 (26) 4062 (26) 2342 (28) 4314 (27) 3132 (27) 1182 ( the state of risk factor management in routine practice. Complete risk factor data were available at index date, and imputations were conducted for only 9% to 19% missing longitudinal data. The results from complete case analyses and imputed data were very similar. Finally, the careful new-user design with a reasonable exposure time of 2 years, and appropriate adjustments for confounders are the primary strengths of the study.
In conclusion, this novel real-world study provides evidence of significant delays in intensification of treatment in patients with T2DM treated with a GLP-1RA. Among HbA1c non-responders, early addition of insulin with GLP-1RA therapy within 6 months resulted in better and sustainable glycaemic control over 2 years. The findings from the present study suggest that, in people requiring treatment intensification on GLP-1RA, the preferred option should be addition of insulin rather than stopping GLP-1RA and switching to insulin therapy.
